Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Impact of custom prime on the PBSC collection efficiency and procedure outcome on Spectra Optia apheresis device by using the CMNC program in low-weight pediatric oncology patients. A single-center experience

Bone Marrow Transplantation volume 55, pages 1665–1667 (2020)Cite this article

Subjects

A Correction to this article was published on 06 July 2023

This article has been updated

Regardless of the considerable experience with PBSC collection in adults, apheresis in low-weight children remains challenging. The main obstacles are difficulties in obtaining adequate venous access, hemodynamic and metabolic changes, and patient’s tolerance [1].

The COBE Spectra MNC (Terumo BCT, Lakewood, Co) was the most commonly used apheresis system in pediatrics. Since 2010, a new system, Spectra Optia (Terumo BCT, Lakewood, CO), was developed. It supports the two-step MNC, and the new one, continuous MNC protocol (CMNC). The CMNC protocol in pediatrics is still of limited experience, but in practice, it showed comparable [2, 3] or even higher [4] collection efficiency (CE) in comparison with MNC. Moreover, CMNC protocol had higher predictability of cell yield concerning the pre-apheresis CD34+ cells [2, 4], higher throughput [5] (collection rate of cells per time), and shorter run times with lower and more predictable product volume [2,3,4]. On the other hand, the higher product hematocrit [2] and higher maximal extracorporeal volume (ECV) of CMNC (297 ml) versus one in MNC (191 ml), could be seen as the potential drawbacks, but both disadvantages can be managed relatively easy. According to literature, the RBC in product never exceeded 20 ml2, which is suitable even in allogeneic settings and, custom prime with allogeneic blood (BP) of the extracorporeal circuit (ECC) can effectively prevent severe hemodynamic changes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

References

  1. Diaz MA, Kanold J, Vicent MG, Halle P, Madero L, Deméocq F. Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients. A state-of-the-art review. Bone Marrow Transpl. 2000;26:1291–8.

    Article  CAS  Google Scholar 

  2. Preslar AM, Homsombath AA, Hsieh FF, Roig J, Boyer M, Couirel DR, Reems J.-A. Comparison of the continuous mononuclear cell and mononuclear cell protocols on the Spectra Optia apheresis system for collecting autologous and allogeneic peripheral blood stem cells (PBSCs). Biol Blood Marrow Transplant. 2018;24:S 119–S 290. (abstract 193).

    Article  Google Scholar 

  3. Westbrook L, Roig J, Bagamasbad N, Dilag R, Nasser M, Sauthoff S, et al. Comparison of the Terumo BCT MNC and cMNC protocols for peripheral Blood stem cell collections. Blood. 2016;128:5731.

    Article  Google Scholar 

  4. Shaughnessy PJ, Nagy G, Stevens D, West C, Nalty MK, Blunk B, et al. Retrospective comparative analysis of Spectra Optia MNC and CMNC apheresis collection protocols. Biol Blood Marrow Transpl. 2017;23:S18–S391. (abstract 484)

    Article  Google Scholar 

  5. Rox JM, Kobbe G, Dienst A, Fisher JC. Comparison of two programs (Spectra Optia cMNC and MNC) for peripheral blood progenitor collection in autologous patients. Transf Med Hemother. 2015;42:1–64.

    Google Scholar 

  6. Sutherland DR, Keeney M, Gratama JW. Enumeration of CD34+ hematopoietic stem and progenitor cells. Curr Protoc Cytom. 2003;6:6.4.1–6.4.24.

    Google Scholar 

  7. Cousins AF, Sinclair JE, Alcorn MJ, Green RHA, Douglas KW. HPC-A dose prediction on the Optia® cell separator based on a benchmark CE2 collection efficiency: promoting clinical efficiency, minimizing toxicity, and allowing quality control. J Clin Apher. 2015;30:321–8.

    Article  PubMed  Google Scholar 

  8. Rosenbaum ER, O´Connell B, Cottler-Fox M. Validation of a formula for predicting daily CD34 (+) cell collection by leukapheresis. Cytotherapy. 2012;14:461–6.

    Article  CAS  PubMed  Google Scholar 

  9. Sanderson F, Poullin P, Smith R, Nicolino-Brunet C, Philip P, Chaib A et al. Peripheral blood stem cell collection on Spectra Optia apheresis system using the continuous mononuclear collection protocol: a single center report of 39 procedures. J Clin Apher. 2017;32:182–90.

  10. Lisenko K, Pavel P, Bruckner T, Puthenparambil J, Hundemer M, Schmitt A, et al. Comparison between intermittent and continuous Spectra Optia leukapheresis systems for autologous peripheral blood stem cell collection. J Clin Apher. 2017;32:27–34.

    Article  PubMed  Google Scholar 

  11. Bojanic I, Besson N, Vidovic I, Golubic Cepulic B. Performance prediction algorithm for autologous PBSC collection in adults and pediatric patients using large volume leukapheresis. J Clin Apher. 2019;34:407–15.

  12. Hester J. Peripheral blood stem cell collection: the interaction of technology, procedure and biological factors. Transfus Sci. 2000;23:125–32.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Therapeutic Services, Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia

    Ana Milojković & Marko Cukjati

  2. Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

    Ana Milojković & Janez Jazbec

  3. Department of Oncology and Haematology, University Children’s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

    Janez Jazbec & Vladan Rajić

Authors
  1. Ana Milojković
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marko Cukjati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janez Jazbec
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vladan Rajić
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana Milojković.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: An affiliation was added and the assignment of authors Ana Milojković and Janez Jazbec was corrected.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Milojković, A., Cukjati, M., Jazbec, J. et al. Impact of custom prime on the PBSC collection efficiency and procedure outcome on Spectra Optia apheresis device by using the CMNC program in low-weight pediatric oncology patients. A single-center experience. Bone Marrow Transplant 55, 1665–1667 (2020). https://doi.org/10.1038/s41409-020-0815-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0815-7

Search

Advanced search

Quick links